discovery appoints Tilmann Burckstummer as new Chief Executive Officer

Tilmann Burckstummer will lead the expansion of discovery as the company enters a new phase of growth with the goal of establishing discovery as a sustainable international business. discovery announced today that Tilmann Burckstummer has been appointed as the new Chief Executive Officer of the company. Tilmann steps up from his current role as Chief Scientific Officer and will assume responsibilities on January 17. Thomas Moser, former Chief Executive Officer, will continue serving discovery as Chief Financial Officer and Chief Operating Officer.

Tilmann Bürckstümmer is a seasoned biotech professional who held key roles at Haplogen and Horizon Discovery. In 2018, he co-founded Myllia Biotechnology, where he led the development of a technology platform that has formed the basis for Myllia’s commercial success. Tilmann has been with discovery since its inception in 2020 and has played a key role in the company’s success to date. He has a deep knowledge of the biotech industry and a keen understanding of the challenges and opportunities facing discovery.

 “We are delighted to have Tilmann in this new role. His experience will be instrumental in driving the growth and long-term success of discovery's business“, says Mark Kotter, CEO of and board member of discovery.

“CRISPR screens have become the primary discovery engine in modern biology, but the quality of the screens is a function of the quality of the cells. Using physiologically relevant stem cell-derived models will empower the discovery of novel drug targets that have a higher chance of delivering drugs in future”, says Tilmann Burckstummer.

“I am grateful to Thomas Moser for his contributions, and we will continue to work closely together during this exciting new phase for discovery. His experience is invaluable” , says Tilmann Burckstuemmer. discovery combines unbiased functional genomic screening with the best human cellular models available, to identify critical genes and pathways driving disease states or provide unique insights into the mechanism of action of drugs. It utilizes stem cells and stem cell-derived cells for the discovery of novel drug targets.


Tel: +44 (0) 1223 787297

Die inhaltliche Verantwortung für diesen Beitrag liegt ausschließlich beim Aussender. Beiträge können Vorhersagen enthalten, die auf Erwartungen an zukünftige Ereignisse beruhen, die zur Zeit der Erstellung des Beitrags in Aussicht standen. Bitte verlassen Sie sich nicht auf diese zukunftsgerichteten Aussagen.

Als Life Sciences Organisation mit Sitz in Wien möchten Sie, dass LISAvienna auf Ihre News und Events hinweist? Senden Sie uns einfach Ihre Beiträge an news(at)